EAN 2021 | Challenges in biomarker development for Alzheimer’s disease

Femke Bouwman, MD, PhD, Amsterdam UMC, Amsterdam, The Netherlands, outlines some of the challenges hindering the development of biomarkers for diagnosis and disease monitoring in Alzheimer’s disease. As well as a lack of funding, the need for long longitudinal studies to reliably identify biomarkers is a major hurdle. Alzheimer’s disease begins many years before patients begin to experience dementia symptoms, so long-term studies are crucial to identify a biomarker that detects Alzheimer’s in its early stages. This interview took place during the European Academy of Neurology 2021 congress.